Sasha Jovanovic
4 min read
BrightSpring Health Services just delivered the kind of quarter that forces short term traders to look up from their screens. The stock jumped 11.1% in regular trading after its Q3 2026 report, extending an already strong run into the print. That price move came as investors reacted to a clean headline beat with revenue of about US$4.2b and adjusted EBITDA of US$228m, both tied to robust pharmacy and home health performance.
The bigger story sits beyond today’s pop. With trailing basic EPS now at US$1.51 and net profit margin near 2%, the real question is how long term holders weigh this improving earnings base against valuation and debt pressure that still sit in the background.
Love BrightSpring Health Services’ growing earnings base but uneasy about the debt and thin margins? You can benchmark BTSG against a curated group of companies that pair profitability with sturdier balance sheets in our list of solid balance sheet and fundamentals stocks (24 results).
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025): US$4,213.2m vs. US$3,334.1m (+26.4%)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$100.6m vs. US$38.1m (very large increase, roughly 2.6x)
-
Basic EPS (Q3 2026 vs. Q3 2025): US$0.49 vs. US$0.19 (up about 160%)
-
Adjusted EBITDA (Q3 2026 vs. Q3 2025): US$228m vs. about US$160.6m (+42%)
Prefer clear charts instead of another wall of tables and EPS figures? See BrightSpring Health Services’ full visual breakdown, including how the current valuation compares with its recent earnings power, in our company report for BrightSpring Health Services.
Evaluating BrightSpring’s Infusion And Cash Flow Milestones
The bullish script argues that BrightSpring Health Services wins if execution in specialty drugs, infusion and home care stays tight, while policy pressure is absorbed by better efficiency and disciplined deals.
“The main thing that has to go right is that BrightSpring Health Services maintains strong execution in specialty LDDs, infusion volume growth and home health quality, while offsetting IRA-related revenue headwinds with efficiency gains and acquisitions.”
Q3 results move this claim from theory toward evidence. Specialty and Infusion scripts climbed 29% with revenue per script and gross profit per script both higher, while IRA pressure in Home & Community Pharmacy still coincided with double digit EBITDA growth. Provider Services grew fast, helped by Amedisys and LHC branches, and operating cash flow of US$204m plus leverage at 1.79x shows the balance sheet already supporting the playbook.
